Microbot Medical Enters Agreement with Lovell Government Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Microbot Medical has entered into an agreement with Lovell Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration, a division of the U.S. Department of Veteran Affairs, the Military Health System, which is run by the U.S. Department of Defense, and the U.S. Indian Health Service. Lovell Government Services will become company's Service-Disabled Veteran-Owned Small Business vendor to serve these customers through federal contracting systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.880
Low
5.50
Averages
8.75
High
12.00
Current: 1.880
Low
5.50
Averages
8.75
High
12.00
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Microbot Medical Expands LIBERTY System Adoption in Michigan
- Market Expansion: Microbot Medical announced the adoption of its LIBERTY® Endovascular Robotic System by one of the largest healthcare systems in Michigan, marking a significant acceleration in the system's rollout across the Midwest U.S., reflecting growing recognition among health systems for advanced robotic solutions.
- Increasing Demand: With approximately 2.5 million peripheral endovascular procedures performed annually in the U.S., Microbot believes this ongoing market expansion indicates a rising demand for integrating robotic technology into routine vascular care, suggesting strong future growth potential for the company.
- Regulatory Approval: The LIBERTY System recently received regulatory approval from the Israeli Ministry of Health's AMAR Division, allowing the company to market and sell the system in Israel, which not only broadens its market reach but also enhances its global business flexibility.
- Strategic Positioning: CEO Harel Gadot stated that the expansion of the LIBERTY System enhances procedural workflow efficiency while supporting physician well-being, further solidifying Microbot Medical's market position in the medical robotics sector.
See More
Microbot Medical Secures First Customer in North Carolina
- Market Expansion: Microbot Medical has successfully secured its first customer in North Carolina, marking a significant broadening of its LIBERTY® Endovascular Robotic System's penetration in the Southeast and Mid-Atlantic regions, indicating strong growth potential in the medical device sector.
- Client Network: The new customer operates a multi-hospital network that provides state-of-the-art patient care across the state, further validating the unique advantages of the LIBERTY system and likely attracting more healthcare systems to consider its adoption.
- Commercial Strategy Execution: The addition of the North Carolina account is viewed as a significant advancement in Microbot's ongoing commercial strategy, with CEO Harel Gadot noting a rapid increase in new accounts following the full market release, reflecting robust market demand.
- Future Outlook: The company plans to penetrate other major metropolitan markets, aiming to attract leading academic institutions in the U.S. to adopt the LIBERTY system, which is expected to drive future revenue growth and enhance market share.
See More
Israel Approves LIBERTY System for Marketing
- Regulatory Milestone: Israel becomes the second jurisdiction to approve the LIBERTY System after the U.S., with the marketing clearance granted by the Israeli Ministry of Health's AMAR Division marking a significant advancement in the company's international market expansion, expected to drive future commercial activities.
- Market Expansion Support: This approval enables Microbot Medical to obtain a Free Sale Certificate, thereby supporting submissions and commercial activities in additional jurisdictions, enhancing its competitiveness in the global market.
- CE Mark Certification Process: The company is actively pursuing CE Mark certification, aiming for completion by the end of 2026, which will lay the groundwork for the next phase of commercial expansion into the EU market, demonstrating its commitment to international markets.
- Success in U.S. Market: The successful launch of the LIBERTY System in the U.S. has already led to adoption by multiple hospitals in states like Georgia, Florida, and New York, indicating strong recognition and demand for the system in the healthcare industry, further propelling the implementation of the company's growth strategies.
See More
Microbot Medical to Host Analyst Conference Call on LIBERTY System
- Conference Call Scheduled: Microbot Medical will host an analyst and investor conference call on May 18, 2026, at 3:00 PM ET to review the progress of the LIBERTY® Endovascular Robotic System's market release, ensuring investors receive accurate information and correcting misleading statements from a recent third-party article.
- Expert Participation: The call will be led by Chairman and CEO Harel Gadot, with vascular surgeon Dr. Charles Briggs sharing his experiences using the LIBERTY System, highlighting its practical applications and significance in clinical settings.
- Transparency in Information: Microbot Medical plans to review claims made in the third-party article to correct misunderstandings about its products and technology, ensuring investors are fully informed of the company's actual situation, thereby enhancing market confidence.
- Technological Innovation: The LIBERTY System, as the first single-use, remotely operated robotic solution, aims to improve precision and safety in endovascular procedures, with Microbot Medical driving the future of endovascular care through ongoing technological advancements.
See More
Microbot Medical Reports Q1 Loss, Shares Drop 17%
- Disappointing Earnings: Microbot Medical (MBOT) reported a Q1 loss of $0.05, an improvement from a loss of $0.08 a year earlier, yet still falling short of market expectations, resulting in a 17% drop in share price.
- Market Release Progress: The company initiated the full market release of the LIBERTY system in Q2, with revenue halfway through Q2 already exceeding total Q1 revenue, indicating improved market acceptance of the product.
- Short Report Impact: White Diamond Research disclosed its short position in Microbot (MBOT), exacerbating negative market sentiment and leading to a decline in investor confidence.
- Short Interest Situation: Microbot has a short interest of 12.8%, reflecting market concerns about its future performance, which could impact its financing capabilities and stock price stability.
See More
Microbot Medical Reports Significant Revenue Growth in Q2
- Market Release Impact: Microbot Medical's revenue for Q2 2026 has already surpassed Q1, driven by the Full Market Release of the LIBERTY System, indicating accelerated utilization and adoption across multiple sales territories.
- Increase in Customer Orders: The company reports a significant rise in recurring customer orders and new accounts, with a growing pipeline of potential future accounts, reflecting sustained market demand for the LIBERTY System.
- Diverse Procedures: The LIBERTY System has been adopted in hospitals across six states, performing complex surgeries including the world's first robotic Prostatic Artery Embolization, further validating its value and application potential in the medical field.
- Enhanced Industry Support: With updated guidelines on occupational radiation and musculoskeletal protection adopted by at least nine medical societies, commercial adoption of the LIBERTY System is expected to accelerate, bolstered by the upcoming Global Embolization Symposium, facilitating the company's market growth.
See More
Microbot Medical Expands LIBERTY System Adoption in Michigan
- Market Expansion: Microbot Medical announced the adoption of its LIBERTY® Endovascular Robotic System by one of the largest healthcare systems in Michigan, marking a significant acceleration in the system's rollout across the Midwest U.S., reflecting growing recognition among health systems for advanced robotic solutions.
- Increasing Demand: With approximately 2.5 million peripheral endovascular procedures performed annually in the U.S., Microbot believes this ongoing market expansion indicates a rising demand for integrating robotic technology into routine vascular care, suggesting strong future growth potential for the company.
- Regulatory Approval: The LIBERTY System recently received regulatory approval from the Israeli Ministry of Health's AMAR Division, allowing the company to market and sell the system in Israel, which not only broadens its market reach but also enhances its global business flexibility.
- Strategic Positioning: CEO Harel Gadot stated that the expansion of the LIBERTY System enhances procedural workflow efficiency while supporting physician well-being, further solidifying Microbot Medical's market position in the medical robotics sector.
See More
Microbot Medical Secures First Customer in North Carolina
- Market Expansion: Microbot Medical has successfully secured its first customer in North Carolina, marking a significant broadening of its LIBERTY® Endovascular Robotic System's penetration in the Southeast and Mid-Atlantic regions, indicating strong growth potential in the medical device sector.
- Client Network: The new customer operates a multi-hospital network that provides state-of-the-art patient care across the state, further validating the unique advantages of the LIBERTY system and likely attracting more healthcare systems to consider its adoption.
- Commercial Strategy Execution: The addition of the North Carolina account is viewed as a significant advancement in Microbot's ongoing commercial strategy, with CEO Harel Gadot noting a rapid increase in new accounts following the full market release, reflecting robust market demand.
- Future Outlook: The company plans to penetrate other major metropolitan markets, aiming to attract leading academic institutions in the U.S. to adopt the LIBERTY system, which is expected to drive future revenue growth and enhance market share.
See More
Israel Approves LIBERTY System for Marketing
- Regulatory Milestone: Israel becomes the second jurisdiction to approve the LIBERTY System after the U.S., with the marketing clearance granted by the Israeli Ministry of Health's AMAR Division marking a significant advancement in the company's international market expansion, expected to drive future commercial activities.
- Market Expansion Support: This approval enables Microbot Medical to obtain a Free Sale Certificate, thereby supporting submissions and commercial activities in additional jurisdictions, enhancing its competitiveness in the global market.
- CE Mark Certification Process: The company is actively pursuing CE Mark certification, aiming for completion by the end of 2026, which will lay the groundwork for the next phase of commercial expansion into the EU market, demonstrating its commitment to international markets.
- Success in U.S. Market: The successful launch of the LIBERTY System in the U.S. has already led to adoption by multiple hospitals in states like Georgia, Florida, and New York, indicating strong recognition and demand for the system in the healthcare industry, further propelling the implementation of the company's growth strategies.
See More
Microbot Medical to Host Analyst Conference Call on LIBERTY System
- Conference Call Scheduled: Microbot Medical will host an analyst and investor conference call on May 18, 2026, at 3:00 PM ET to review the progress of the LIBERTY® Endovascular Robotic System's market release, ensuring investors receive accurate information and correcting misleading statements from a recent third-party article.
- Expert Participation: The call will be led by Chairman and CEO Harel Gadot, with vascular surgeon Dr. Charles Briggs sharing his experiences using the LIBERTY System, highlighting its practical applications and significance in clinical settings.
- Transparency in Information: Microbot Medical plans to review claims made in the third-party article to correct misunderstandings about its products and technology, ensuring investors are fully informed of the company's actual situation, thereby enhancing market confidence.
- Technological Innovation: The LIBERTY System, as the first single-use, remotely operated robotic solution, aims to improve precision and safety in endovascular procedures, with Microbot Medical driving the future of endovascular care through ongoing technological advancements.
See More
Microbot Medical Reports Q1 Loss, Shares Drop 17%
- Disappointing Earnings: Microbot Medical (MBOT) reported a Q1 loss of $0.05, an improvement from a loss of $0.08 a year earlier, yet still falling short of market expectations, resulting in a 17% drop in share price.
- Market Release Progress: The company initiated the full market release of the LIBERTY system in Q2, with revenue halfway through Q2 already exceeding total Q1 revenue, indicating improved market acceptance of the product.
- Short Report Impact: White Diamond Research disclosed its short position in Microbot (MBOT), exacerbating negative market sentiment and leading to a decline in investor confidence.
- Short Interest Situation: Microbot has a short interest of 12.8%, reflecting market concerns about its future performance, which could impact its financing capabilities and stock price stability.
See More
Microbot Medical Reports Significant Revenue Growth in Q2
- Market Release Impact: Microbot Medical's revenue for Q2 2026 has already surpassed Q1, driven by the Full Market Release of the LIBERTY System, indicating accelerated utilization and adoption across multiple sales territories.
- Increase in Customer Orders: The company reports a significant rise in recurring customer orders and new accounts, with a growing pipeline of potential future accounts, reflecting sustained market demand for the LIBERTY System.
- Diverse Procedures: The LIBERTY System has been adopted in hospitals across six states, performing complex surgeries including the world's first robotic Prostatic Artery Embolization, further validating its value and application potential in the medical field.
- Enhanced Industry Support: With updated guidelines on occupational radiation and musculoskeletal protection adopted by at least nine medical societies, commercial adoption of the LIBERTY System is expected to accelerate, bolstered by the upcoming Global Embolization Symposium, facilitating the company's market growth.
See More
